Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on NAMS stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s promising future prospects. The company reported strong financials for the second quarter of 2025, with a robust cash position of approximately $783 million, which is expected to support its operations through significant upcoming milestones. These include the top-line readout of the PREVAIL CV outcomes trial in the second half of 2026 and preparations for the U.S. launch of obicetrapib (obi).
Additionally, the company has demonstrated compelling data from various studies, including the BROADWAY and TANDEM trials, which were presented at the European Atherosclerosis Society congress. The positive Alzheimer’s disease biomarker analysis from the BROADWAY trial showed significant reductions in p-tau217 levels, further enhancing obi’s differentiated profile. The upcoming Phase 3 RUBENS trial in diabetes patients also expands the potential market for obi, which is seen as a potentially transformative oral therapy for cardiovascular disease due to its once-daily administration, ability to reduce LDL-C and other atherogenic particles, potential to lower diabetes risk, and clean safety profile.
Ruiz covers the Healthcare sector, focusing on stocks such as United Therapeutics, NewAmsterdam Pharma Company, and Aquestive Therapeutics. According to TipRanks, Ruiz has an average return of -7.2% and a 39.26% success rate on recommended stocks.
In another report released yesterday, Scotiabank also reiterated a Buy rating on the stock with a $52.00 price target.